TD Cowen Maintains Hold on Ginkgo Bioworks Holdings, Raises Price Target to $11
TD Cowen analyst Brendan Smith maintains Ginkgo Bioworks Holdings (NYSE:DNA) with a Hold and raises the price target from $9 to $11.
Stocks · News reference
Ginkgo Bioworks To Integrate Araceli Biosciences' Endeavor High-Content Imaging Instrument Into Nebula, The Company's Autonomous Lab
The Endeavor, the world's fastest high-content imaging system, brings cellular imaging with real-time analysis to Nebula's existing technologies, giving researchers the large, curated datasets needed to train
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.
What's Going on With Ginkgo Bioworks Stock on Friday?
Ginkgo Bioworks offers remote autonomous lab access to NSF X-Labs and integrates Araceli imaging into its Boston platform.
Ginkgo Bioworks shares are trading higher after the company announced that it will provide in-kind access to its autonomous laboratory in Boston to support the National Science Foundation’s X-Labs program.